China published guidance on human organoid research, offering regulatory and bioethical direction for organoid generation, use, and oversight, the analysis reported. The guidelines address consent, provenance of human cells, and permissible experimental manipulations, positioning China among nations clarifying policy around rapidly advancing organoid science. Authors of the global perspective noted implications for international collaborations, multicenter studies, and biotech companies developing organoid‑based assays or therapeutics. The guidance may influence tissue sourcing, data governance, and commercial development pathways for organoid platforms worldwide.